A Phase I/II Open-Label, Dose Escalation and Dose Optimization Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD8359, a CD8-Guided T Cell Engaging Antibody that Targets STEAP2, in Adult Participants with Prostate Cancer (CRIUS-1)

Clinical Trial Information

Trial Phone: 321-841-7246

Principal Investigator: Jad Chahoud, MD

Phase: I/II

Age Group: ADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT07529717

Objective

The objective of this clinical trial is to evaluate the safety and tolerability of AZD8359, identify dose limiting toxicities, and determine either the maximum tolerated dose or recommended doses for expansion when given alone or in combination in participants with prostate cancer. The study also aims to optimize dosing in Part B and assess preliminary anti tumor activity of AZD8359. Together, these assessments will guide the appropriate dose and potential therapeutic benefit of AZD8359 in this patient population.

Share:

Related Clinical Trials

A Phase III Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
An Interventional Open-Label Phase Ib/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in Combination with Different Anticancer Agents in Participants with Advanced Solid Tumors
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
A Dose Escalation Study Using Difluoromethylornithine (DFMO) and AMXT-1501 followed by a Randomized Controlled Trial of DFMO with or without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas